The Aleksandrovska University Hospital is a university hospital in Sofia, the capital of Bulgaria. It was founded in 1879 and was named after the Bulgarian Prince Alexander I Battenberg in October 1884. A military hospital between 1912 and 1919, it was the site where the Sofia Medical University was founded in 1917.

There are 1,100 beds in University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD.

During the past decade, University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD conducted 85 clinical trials. In the 10-year time frame, 85 clinical trials started and 42 clinical trials were completed, i.e. on average, 49.4% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 32 clinical trials were completed. i.e. 91.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD" #1 sponsor was "Amgen" with 10 trials, followed by "Actelion" with 7 trials sponsored, "Bayer" with 7 trials sponsored, "Celgene" with 7 trials sponsored and "Janssen Research & Development, LLC" with 7 trials sponsored. Other sponsors include 70 different institutions and companies that sponsored additional 53 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "APCER Life Sciences" with 1 trials as a collaborator, "Arbutus Biopharma Corporation" with 1 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "Astellas Pharma Inc" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD" are "Ulcerative Colitis" (7 trials), "Arthritis, Psoriatic" (3 trials), "Bipolar I Disorder" (3 trials), "Crohn Disease" (3 trials) and "Crohn's Disease" (3 trials). Many other conditions were trialed in "University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD" in a lesser frequency.

Most popular intervention types in "University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD" are "Drug" (101 trials), "Other" (13 trials), "Biological" (7 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (48 trials), "Ozanimod" (6 trials), "Ontamalimab" (4 trials), "Dexamethasone" (3 trials) and "Guselkumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD" are 107 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD". 1 are not yet recruiting, 21 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 59 completed trials in University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD, 2 "Phase 1" clinical trials were conducted, 32 "Phase 2" clinical trials and 72 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".